OncoHealth is a technology company.
OncoHealth has raised $49.0M across 2 funding rounds.
OncoHealth has raised $49.0M in total across 2 funding rounds.
OncoHealth has raised $49.0M in total across 2 funding rounds.
OncoHealth's investors include 125 Ventures, 14W, Audrey Capital, Baird Capital, BBG Ventures, Bond, BoxGroup, Dragoneer Investment Group, F-Prime Capital Partners, Future Perfect Ventures, General Catalyst, GenNx360.
OncoHealth is a digital health company specializing in oncology, offering an integrated software and services platform for oncology value management, utilization management, and virtual cancer care.[1][2][4] It builds products like OneUM™ for streamlining prior authorizations and evidence-based treatment reviews, and Iris™ for 24/7 supportive care including oncology nursing, mental health, nutrition, and resource navigation.[2][3][5] Serving health plans, employers, providers, patients, and life science researchers—supporting over 8 million people in the US and Puerto Rico—OncoHealth solves key challenges in cancer care: ensuring appropriate treatments to cut costs, reducing administrative burdens, addressing physical/mental side effects, and improving access in underserved areas like counties without oncologists.[1][3][4][5] The company demonstrates strong growth, expanding from data analytics roots to telehealth innovations and partnerships with health plans.[3][5][6]
Founded in 2009 and based in Atlanta, Georgia, OncoHealth evolved from Oncology Analytics, a data analytics and technology-enabled services firm focused on evidence-based utilization management for cancer treatments.[1][6] It pioneered tools like the OneUM platform, which normalized clinical data (e.g., EMR notes, biomarkers) and used machine learning to support prior authorizations for 5 million members across all cancer types and therapies.[6] Pivotal moments include launching Iris™ in 2022 as a consumer-facing telehealth platform, partnering with health plans for personalized supportive care, and scaling to power the nation's first oncology-focused 50-state virtual medical group.[1][3] Leadership, including CEO Mr. Maack with expertise in healthcare scaling and CMO Andrew Norden, MD, has driven its shift toward comprehensive virtual care amid rising oncology complexities.[1][3]
OncoHealth rides the digital health wave in oncology, where rising cancer prevalence (32 million Americans in oncologist-scarce areas) meets demands for value-based care amid exploding therapy costs and complexity.[3][5][6] Its timing aligns with telehealth acceleration post-pandemic, AI-driven personalization, and payer shifts toward utilization management to curb 5-10x costlier inappropriate treatments.[2][6] Market forces like biomarker-driven precision medicine and real-world data needs favor its analytics edge, influencing the ecosystem by enabling health plans to optimize networks, reduce disparities, and integrate supportive care—positioning it as a bridge between payers, providers, and patients in a $200B+ US oncology market.[1][4][6]
OncoHealth is poised for expansion through deeper health plan integrations, Iris scaling to more members, and leveraging real-world data for life sciences amid AI advancements in oncology.[1][3][5] Trends like virtual care mandates, value-based reimbursement, and personalized medicine will propel growth, potentially evolving its influence via acquisitions or platform APIs for broader ecosystems. As a pure-play oncology leader, it stands to lower cancer's toll further, reinforcing its mission from day one: right care, right time, right cost.[2][4]
OncoHealth has raised $49.0M across 2 funding rounds. Most recently, it raised $28.0M Series C in May 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2020 | $28.0M Series C | 125 Ventures, 14W, Audrey Capital, Baird Capital, BBG Ventures, Bond, BoxGroup, Dragoneer Investment Group, F-Prime Capital Partners, Future Perfect Ventures, General Catalyst, GenNx360, GE Ventures, Great Oaks Venture Capital, Hoxton Ventures, Lux Capital, Oak HC/FT, Sequoia Capital, Supply Change Capital, Target Global, Teamworthy Ventures, Anne Wojcicki, Jeremy Yap, Julie McDermott | |
| Nov 1, 2018 | $21.0M Series B | 125 Ventures, 14W, Audrey Capital, BBG Ventures, Bond, BoxGroup, Dragoneer Investment Group, Future Perfect Ventures, General Catalyst, GenNx360, GE Ventures, Great Oaks Venture Capital, Hoxton Ventures, Lux Capital, Oak HC/FT, Sequoia Capital, Supply Change Capital, Target Global, Teamworthy Ventures, Anne Wojcicki, Jeremy Yap, Julie McDermott |